201 related articles for article (PubMed ID: 29579036)
1. A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens.
Bouhaddou M; Barrette AM; Stern AD; Koch RJ; DiStefano MS; Riesel EA; Santos LC; Tan AL; Mertz AE; Birtwistle MR
PLoS Comput Biol; 2018 Mar; 14(3):e1005985. PubMed ID: 29579036
[TBL] [Abstract][Full Text] [Related]
2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
3. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
4. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
5. Correction: A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens.
PLOS Computational Biology Staff
PLoS Comput Biol; 2018 Jul; 14(7):e1006189. PubMed ID: 29985911
[TBL] [Abstract][Full Text] [Related]
6. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
9. Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.
Castagnino N; Tortolina L; Balbi A; Pesenti R; Montagna R; Ballestrero A; Soncini D; Moran E; Nencioni A; Parodi S
Curr Cancer Drug Targets; 2010 Nov; 10(7):737-57. PubMed ID: 20578981
[TBL] [Abstract][Full Text] [Related]
10. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
12. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
Pavel AB; Sonkin D; Reddy A
BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
[TBL] [Abstract][Full Text] [Related]
13. Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells.
Kim IH; Nam TJ
Oncol Rep; 2018 Mar; 39(3):1516-1522. PubMed ID: 29328495
[TBL] [Abstract][Full Text] [Related]
14. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor 1 inhibits extracellular signal-regulated kinase to promote neuronal survival via the phosphatidylinositol 3-kinase/protein kinase A/c-Raf pathway.
Subramaniam S; Shahani N; Strelau J; Laliberté C; Brandt R; Kaplan D; Unsicker K
J Neurosci; 2005 Mar; 25(11):2838-52. PubMed ID: 15772344
[TBL] [Abstract][Full Text] [Related]
17. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Hahn M; Li W; Yu C; Rahmani M; Dent P; Grant S
Mol Cancer Ther; 2005 Mar; 4(3):457-70. PubMed ID: 15767555
[TBL] [Abstract][Full Text] [Related]
19. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.
Lin P; Yi Y; Lu M; Wang M; Yang Y; Lu Y; Song S; Zheng Z; Deng X; Zhang L
Anticancer Drugs; 2015 Jan; 26(1):25-34. PubMed ID: 25014191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
